HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigm for liver resection and transplant.
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.